Evidence map›Paper›PMID 33736974›Full record

ArticleExperimental neurology2021

GPR18 drives FAAH inhibition-induced neuroprotection against HIV-1 Tat-induced neurodegeneration.

Douglas J Hermes, Barkha J Yadav-Samudrala, Changqing Xu, Jacqueline E Paniccia, Rick B Meeker, Michael L Armstrong, Nichole Reisdorph, Benjamin F Cravatt, Ken Mackie, Aron H Lichtman and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Experimental neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Douglas J HermesDepartment of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America. Electronic address: aerime@live.unc.edu.
Barkha J Yadav-SamudralaDepartment of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
Changqing XuDepartment of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
Jacqueline E PanicciaDepartment of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
Rick B MeekerDepartment of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
Michael L ArmstrongDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Denver, CO, United States of America.
Nichole ReisdorphDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Denver, CO, United States of America.
Benjamin F CravattDepartment of Chemistry, Scripps Research Institute, La Jolla, CA, United States of America.
Ken MackieDepartment of Psychological and Brain Sciences, Indiana University, Bloomington, IN, United States of America.
Aron H LichtmanDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, United States of America.
Bogna M Ignatowska-JankowskaOkinawa Institute of Science and Technology, Neuronal Rhythms in Movement Unit, Okinawa, Japan.
Donald T LysleDepartment of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
Sylvia FittingDepartment of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America. Electronic address: sfitting@email.unc.edu.
University of North Carolina at Chapel Hill · USUniversity of Colorado Anschutz Medical Campus · USIndiana University Bloomington · USOkinawa Institute of Science and Technology Graduate University · JPScripps Research Institute · USVirginia Commonwealth University · US

Funding

PILOT AND FEASIBILITY STUDIESP30DK034987 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBERT S. SANDLER · 1985 to 2026
$30.5M
Training on Research in Drug AbuseT32DA007244 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Regina M Carelli · 1990 to 2026
$7.6M
CB1 Allosteric Modulators: Molecular, Cellular and In Vivo PharmacologyR01DA039942 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI KINSEY, STEVEN G., LICHTMAN, ARON H · 2016 to 2020
$2.6M
Neural network dysfunction in early HIV neuropathogenesisR01NS108808 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MEEKER, RICK B · 2018 to 2022
$1.9M
Endocannabinoid-mediated neuroprotection in models of neuroAIDS in vivoR01DA045596 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FITTING, SYLVIA · 2018 to 2022
$1.9M
Sensitive Triple Quadrupole Mass Spectrometer for Translational ResearchS10OD010366 · OD · NATIONAL JEWISH HEALTH · PI REISDORPH, NICHOLE A · 2012 to 2012
$443k
A degradomics strategy for the analysis of inflammation-associated neuronal vulnerabilityR21AG056924 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MEEKER, RICK B · 2017 to 2018
$428k
Investigation of endocannabinoid-mediated neuroprotection in models of neuroAIDSR21DA041903 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FITTING, SYLVIA · 2016 to 2017
$407k
NIA NIH HHS R21 AG056924NIDA NIH HHS R01 DA039942NIDA NIH HHS R01 DA045596NIDA NIH HHS R21 DA041903NIDA NIH HHS T32 DA007244NIDDK NIH HHS P30 DK034987NIH HHS S10 OD010366NINDS NIH HHS R01 NS108808
6 · The paper itself

Abstract

Human immunodeficiency virus type 1 (HIV-1) is known to provoke microglial immune responses which likely play a paramount role in the development of chronic neuroinflammatory conditions and neuronal damage related to HIV-1 associated neurocognitive disorders (HAND). In particular, HIV-1 Tat protein is a proinflammatory neurotoxin which predisposes neurons to synaptodendritic injury. Drugs targeting the degradative enzymes of endogenous cannabinoids have shown promise in reducing inflammation with minimal side effects in rodent models. Considering that markers of neuroinflammation can predict the extent of neuronal injury in HAND patients, we evaluated the neurotoxic effect of HIV-1 Tat-exposed microglia following blockade of fatty acid amid hydrolyze (FAAH), a catabolic enzyme responsible for degradation of endocannabinoids, e.g. anandamide (AEA). In the present study, cultured murine microglia were incubated with Tat and/or a FAAH inhibitor (PF3845). After 24 h, cells were imaged for morphological analysis and microglial conditioned media (MCM) was collected. Frontal cortex neuron cultures (DIV 7-11) were then exposed to MCM, and neurotoxicity was assessed via live cell calcium imaging and staining of actin positive dendritic structures. Results demonstrate a strong attenuation of microglial responses to Tat by PF3845 pretreatment, which is indicated by 1) microglial changes in morphology to a less proinflammatory phenotype using fractal analysis, 2) a decrease in release of neurotoxic cytokines/chemokines (MCP-1/CCL2) and matrix metalloproteinases (MMPs; MMP-9) using ELISA/multiplex assays, and 3) enhanced production of endocannabinoids (AEA) using LC/MS/MS. Additionally, PF3845's effects on Tat-induced microglial-mediated neurotoxicity, decreased dysregulation of neuronal intracellular calcium and prevented the loss of actin-positive staining and punctate structure in frontal cortex neuron cultures. Interestingly, these observed neuroprotective effects appeared to be independent of cannabinoid receptor activity (CB

Indexed as

AmidohydrolasesAnimalsAnimals, NewbornCells, CulturedFatty Acid Amide HydrolasesMiceMice, Inbred C57BLMice, KnockoutMicrogliaNeurodegenerative DiseasesNeuroprotectionNeuroprotective AgentsPiperidinesPyridinesReceptors, G-Protein-Coupledtat Gene Products, Human Immunodeficiency VirusAmidohydrolasesFatty Acid Amide HydrolasesGPR18 protein, mouseNeuroprotective AgentsPF 3845PiperidinesPyridinesReceptors, G-Protein-Coupledtat Gene Products, Human Immunodeficiency VirusAnandamideEndocannabinoidFatty acid amide hydrolaseG protein coupled receptorHIV-1 TatMatrix metalloproteinaseMicrogliaMonocyte chemoattractant protein 1NeuroinflammationNeuroprotection

Identifiers

PMID33736974
PMCPMC8984429
OpenAlexW3137349525

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.